MOUNTAIN VIEW, Calif., and GOTHENBURG, Sweden – Glooko’s Mobile Insulin Dosing System has received clearance from the U.S. Food and Drug Administration for people with Type 2 diabetes. The system is an insulin titration application that is accessible through a unified diabetes management platform, providing a complete program for diabetes management. “I am excited that Glooko can now offer MIDS, which helps clinicians support their patients in safely and rapidly attaining optimal glycemic levels,” said Michael Greenfield, chief medical officer at Glooko, in a statement. “In a pre-market study, I used MIDS with my patients and was able to witness both improvements in glucose control and how happy patients were to have an easy tool to help them titrate their insulin dose on their mobile phones.” The MIDS system includes access to a patient’s blood glucose data directly from their glucose meter. It analyzes a patient’s fasting blood glucose levels and recommends insulin dose adjustments based on the HCP’s pre-configured treatment plan and/or published clinical guidelines, so patients can quickly get to their optimal insulin dose. To enhance adherence, MIDS includes customizable in-app reminders to check fasting blood glucose and to take insulin.
You are here: / / Glooko’s mobile insulin dosing system receives FDA clearance